Blood Res.  2019 Sep;54(3):233-236. 10.5045/br.2019.54.3.233.

Characteristics and survival of patients with atypical chronic myeloid leukemia

• Kong JH
• Nam H
• Go TH
• Hyun SY
• Shim KY

• KMID: 2459391
• DOI: http://doi.org/10.5045/br.2019.54.3.233

Abstract

No abstract available.

MeSH Terms

Humans
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative*

Figure

• 

  Fig. 1 Kaplan–Meier plot of 52 patients with atypical chronic myeloid leukemia. (A) The OS of 5 patients who progressed to AML (dotted line) was not different from that of those who did not progress to AML (solid line, N=49, P=0.6839). (B) Patients aged ≤65 years (dotted line) showed better OS than those aged >65 years (solid line, P=0.0053). Abbreviations: AML, acute myeloid leukemia; OS, overall survival.

Reference

1. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev. 2019; 33:74–81.

2. Vardiman JW, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In : Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press;2008. p. 80–81.

3. National Health Insurance Service (NHIS). History of the NHIS. Wonju, Korea: NHIS;2011. Accessed April 10, 2019. at http://www.nhis.or.kr/static/html/wbd/g/a/wbdga0203.html.

4. National Health Insurance Service. Final Report of Academic Research Project. The effect of National Health Examination Program on the early diagnosis of diseases, medical utilization, and health outcome. Seoul, Korea: National Health Insurance Service;2011.

5. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006; 91:1566–1568.

6. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001; 19:2915–2926.

7. Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002; 95:1673–1684.

8. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol. 2015; 6:308–312.

9. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014; 123:2645–2651.

10. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017; 92:542–548.

11. Hernández JM, del Cañizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000; 11:441–444.

12. Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph−) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique. Blood. 1991; 78:205–211.

13. Koldehoff M, Steckel NK, Hegerfeldt Y, Ditschkowski M, Beelen DW, Elmaagacli AH. Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. Int J Lab Hematol. 2012; 34:e3–e5.

14. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004; 33:1005–1009.

15. Dhakal P, Gundabolu K, Amador C, Rayamajhi S, Bhatt VR. Atypical chronic myeloid leukemia: a rare entity with management challenges. Future Oncol. 2018; 14:177–185.